Influenza outbreak

GenEng News  Oct 5  Comment 
Visterra said today it has won a five-year, up-to-$204.5 million contract from the Biomedical Advanced Research and Development Authority (BARDA) toward the development of the company’s Phase IIa lead product candidate VIS410 for seasonal and...
Insurance Journal  Oct 2  Comment 
In Iowa, one of the largest U.S. egg processors has started to buy foreign supplies for the first time. Elsewhere in the Midwest, a free-range egg producer says it may build automatic car washes to scour vehicles accessing its 60 …
NPR  Sep 30  Comment 
A pediatric hospital in Houston is opening a new biocontainment wing — the first in the U.S. designed for children. Kids will even get dolls sporting mini versions of "spacesuits" doctors wear.
Benzinga  Sep 30  Comment 
Maintains Buy and $70.00 PT Latest Ratings for CALM Date Firm Action From To Aug 2015 BB&T Capital Upgrades Hold Buy Jun 2015 DA Davidson Initiates Coverage on Buy May 2015 Stephens &...
GenEng News  Sep 24  Comment 
Understanding the molecular underpinnings of how the influenza virus gains the ability to spread rapidly is critical in controlling outbreaks of the disease. Now, scientists at the Massachusetts Institute of Technology (MIT) and National Institute...
Agriculture Online  Sep 22  Comment 
The highly pathogenic avian influenza (HPAI) outbreak of winter and spring 2015 was the worst animal disease outbreak in U.S. history, affecting more than 48.8 million turkeys and chickens in 21 states, and causing economy-wide losses of an...
Agriculture Online  Sep 21  Comment 
Harrisvaccines has been granted a USDA conditional license for the company’s avian influenza vaccine, RNA. This is the first conditional license for the highly pathogenic avian influenza that swept across the Midwest in the spring of 2015. A...
New York Times  Sep 21  Comment 
The Agriculture Department gave Harrisvaccines a conditional license for a drug to protect chickens from a flu that killed 48 million birds this year.
Forbes  Sep 10  Comment 
Following the dramatic plunge on the Shanghai stock exchange, the big question is whether the world, much of it still growing slowly in the aftermath of the Great Recession, is in for it once again. In a world that once caught a cold only when...


Influenza, or the flu, is a common infectious disease, which can be deadly to individuals with compromised immune systems (the very young, the very old, and those with conditions such as AIDS or Cancer). However, occasionally particularly virulent strains of influenza break out that can be threatening on a much larger scale -- such as the flu epidemic of 1918 and, more recently, concerns that H5N1 "Bird Flu" or H1N1 "Swine Flu" could mutate into a highly-infectious and deadly virus. A number of pharmaceutical companies make treatments for the flu and benefit from the fear of a flu outbreak.

  • Roche Pharmaceuticals makes Tamiflu, an antiviral pill to treat the flu. In 2005, amid concerns that bird flu might pose a large threat during the winter flu season, many national governments began stocking up on Tamiflu. Chugai pharmaceuticals sells Tamiflu in Japan.
  • Novartis AG (NVS), through its acquisition of Chiron in 2006, supplies much of the traditional flu vaccine supply to the United States.
  • AstraZeneca (AZN), through recently acquired MedImmune, manufactures 'FluMist', a novel flu vaccine that is delivered via an intranasal spray rather than via an injection.

Companies with treatments for H1N1, or "Swine Flu"

In April 2009, a novel flu virus, known as "Swine Flu" because it was believed to have originated in pigs, started infecting humans. By April 28th, there were 1,300 confirmed cases of the flu, known by its scientific designation H1N1, in Mexico, and a handful in the U.S. and other parts of the world.

According to preliminary test done by the US Center for Disease Control, Roche Pharmaceuticals (RHHBY)'s Tamiflu and GlaxoSmithKline (GSK)'s Relenza are active against H1N1, although many older drugs are not. [1]


  1. Investors buy up shares of flu drug makers, New York Times, April 27th 2009.
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki